Table 2.
Subgroup analysis for percentage intraocular pressure reduction (IOPR%).
| Group | FDC vs. netarsudil | FDC vs. latanoprost | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of studies | WMD (95% CI) | P | I2 (%) | No. of studies | WMD (95% CI) | P | I2 (%) | |
| Total | 3 | 9.60 (7.86–11.33) | <0.00001 | 48 | 3 | 6.09 (4.40–7.77) | <0.00001 | 0 |
| Follow-up (month) | ||||||||
| <1 | 0 | - | - | - | 0 | - | - | - |
| 1~6 | 2 | 10.81 (8.64–12.98) | <0.00001 | 0 | 2 | 6.34 (4.27–8.40) | <0.00001 | 0 |
| 6~12 | 1 | 7.45 (4.56–10.34) | <0.00001 | - | 1 | 5.59 (2.68–8.50) | 0.0002 | - |
| Loss to follow-up rate | ||||||||
| <10% | 2 | 10.81 (8.64–12.98) | <0.00001 | 0 | 2 | 6.34 (4.27–8.40) | <0.00001 | 0 |
| ≥10% | 1 | 7.45 (4.56–10.34) | <0.00001 | - | 1 | 5.59 (2.68–8.50) | 0.0002 | - |
| Nation | ||||||||
| USA | 3 | 9.60 (7.86–11.33) | <0.00001 | 48 | 3 | 6.09 (4.40–7.77) | <0.00001 | 0 |
| Canada | 1 | 11.43 (8.72–14.14) | <0.00001 | - | 1 | 6.97 (4.40–9.54) | <0.00001 | - |
| Patients | ||||||||
| <300 | 1 | 9.70 (6.08–13.32) | <0.00001 | - | 1 | 5.19 (1.72–8.66) | 0.003 | - |
| 300~500 | 0 | - | - | - | 0 | - | - | - |
| ≥500 | 2 | 9.47 (5.57–13.37) | <0.00001 | 74 | 2 | 6.36 (4.44–8.29) | <0.00001 | 0 |
| Publication year | ||||||||
| 2019~2022 (last 3 years) | 2 | 9.47 (5.57–13.37) | <0.00001 | 74 | 2 | 6.36 (4.44–8.29) | <0.00001 | 0 |
| 2017~2022 (last 5 years) | 2 | 9.47 (5.57–13.37) | <0.00001 | 74 | 2 | 6.36 (4.44–8.29) | <0.00001 | 0 |
| 2012~2022 (last 10 years) | 3 | 9.60 (7.86–11.33) | <0.00001 | 48 | 3 | 6.09 (4.40–7.77) | <0.00001 | 0 |
| Trial Center | ||||||||
| Single | 1 | 9.70 (6.08–13.32) | <0.00001 | - | 1 | 5.19 (1.72–8.66) | 0.003 | - |
| Multiple | 2 | 9.47 (5.57–13.37) | <0.00001 | 74 | 2 | 6.36 (4.44–8.29) | <0.00001 | 0 |
FDC, fixed-dose combination; IOPR%, percentage intraocular pressure reduction; No., number; RR: relative risk; VS., versus; WMD, weighted mean difference; “-”, not available.